Why Is CANDEL THERAPEUTICS (CADL) Stock Moving Today?
By the Top Tier Newswire AI Desk · reviewed against 5 wire stories
CANDEL THERAPEUTICS (CADL) is drawing unusual attention today. Our newswire has captured 5 stories on CADL across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for CADL publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
AI sentiment, last 36h · averaged over 5 stories · 54/100 neutral
The headlines behind the move
Story flow · 5 stories on the wire, last 36h · hover or tap a dot for the headline
2h agoStocktwits NewsBULLISH 67Product/PR
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4
If the FDA approves aglatimagene besadenovec in the treatment of certain patients with prostate cancer, it would mark the company’s first commercial product.
9h agoSEC 8-KNEUTRAL 50General
Candel Therapeutics, Inc. (CADL) files 8-K
Filed: 2026-08-13 AccNo: 0001193125-26-347957 Size: 371 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
9h agoSeeking AlphaBEARISH 34Earnings
Candel Therapeutics GAAP EPS of -$0.52 misses by $0.29
Candel Therapeutics (CADL) Q2 GAAP EPS missed, but cash runway to Q1 2028 supports potential aglatimagene launch in 2027—read the update now.
9h agoBusiness InsiderBULLISH 56Product/PR
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 2026
1d agoStocktwits NewsBULLISH 63Product/PR
CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity
Shares of Candel have drawn rising attention as the company advances its experimental immunotherapy, known as CAN-2409 or aglatimagene, toward potential approval in localized prostate cancer.
Frequently asked questions
Why is CADL stock moving today?
CANDEL THERAPEUTICS (CADL) is drawing unusual attention today. Our newswire has captured 5 stories on CADL across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100). The most recent driver: "CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4" (Stocktwits News).
Is CADL a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of CADL coverage reads 54/100 over 5 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →